Calidi Biotherapeutics
CLDI
Market cap $9.78M

1.05 USD

+0.01

0.96%

At close Oct 15, 4:00 PM EDT

After hours

1.04

-0.01

0.95%

1 day

0.96%

5 days

2.94%

1 month

-11.02%

3 months

-40.00%

6 months

-82.50%

Year to date

-92.71%

1 year

-96.50%

5 years

-97.86%

About: Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Employees: 41

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

11% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 9

3% more funds holding

Funds holding: 31 [Q1] → 32 (+1) [Q2]

3.54% less ownership

Funds ownership: 7.72% [Q1] → 4.18% (-3.54%) [Q2]

50% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 8

66% less capital invested

Capital invested by funds: $1.54M [Q1] → $523K (-$1.02M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CLDI.

See Analyst Rankings

Financial journalist opinion

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSEAM: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today reported its operating and financial results for the second quarter ended June 30, 2024, and reviewed recent business highlights.

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (Nasdaq:GP) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 3, at 7 p.m. Eastern Time (ET).

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, announced a $2 million strategic investment by Dr. Ronald Rigor into its new subsidiary, Nova Cell, Inc. (“Nova Cell”), to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs. Dr Rigor also invested an additional $1 million into Calidi to further its oncology pipeline of assets.

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic.

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to Calidi

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi to Effect Reverse Stock Split

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi to Effect Reverse Stock Split.

Calidi to Effect Reverse Stock Split

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors.

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13.

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors.

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi's Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

SAN DIEGO--(BUSINESS WIRE)---- $CLDI #immunotherapy--Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting.

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

See News Rankings

Charts implemented using Lightweight Charts™